Speakers:

Presentations:

A. Khanani USA

13:00 – 13:05
Introductions and Objectives

A. Tufail UK

13:05 – 13:20
wAMD: Where are we today
• Disease Overview

G. Cheung SINGAPORE

13:20 – 13:35
Most recent and emerging Treatments in wAMD
• Treatment objectives for innovation in nAMD
• Review of most recent treatments
• Review of emerging treatments in Phase 3

A. Loewenstein ISRAEL

13:35 – 13:50
Sozinibercept (OPT-302): An emerging therapy with the potential to raise the standard of care benchmark in visual outcomes
• An introduction to sozinibercept, a novel anti-VEGF C&D inhibitor
• Phase 2 data review
• Phase 3 Overview: Study Title and Objectives

A. Khanani USA

13:50 – 14:00
Panel Discussion